EPA Registers Spinach-Based Citrus Greening Treatment
The treatment uses modified citrus viruses to induce protective compounds, with field trials in Florida slated for late 2026.
Updated on Oct. 26, 2026 in Botany
Live Poll
Should the agriculture industry prioritize adopting new biological treatments to combat crop diseases?
The Environmental Protection Agency has registered a new treatment for citrus greening disease that uses compounds found in spinach. This research-stage method, which does not alter the tree's genetic makeup, is slated for field trials in Florida.
Why it matters
Citrus greening is a significant threat to the citrus industry, and this regulatory registration enables new field-scale testing of a non-GMO biological intervention. The treatment leverages natural compounds that have shown potential in inhibiting the bacteria that cause the disease.
The treatment utilizes a modified citrus virus to induce internal production of spinach-derived compounds, the culmination of 15 years of development. The efficacy of these compounds against the bacteria driving citrus greening remains the primary metric for upcoming trials.
The players
Environmental Protection Agency
The federal agency responsible for overseeing environmental regulations and pesticide registrations in the United States.
Silvec Biologics
A biotechnology firm focused on developing and commercializing biological solutions for agricultural disease management.
Texas A&M AgriLife Research
The agricultural research agency of Texas A&M University, focused on crop resilience and pathology.
University of Florida
A public research university with an extensive agricultural program serving the state's citrus industry.
The details
The process functions by introducing a modified citrus virus into a tree through grafting. This virus acts as a vector—a delivery mechanism—that prompts the tree to synthesize protective compounds typically found in spinach. Importantly, the intervention does not edit the plant's genome, maintaining the tree as a non-GMO organism while using the internal plant machinery to combat the bacterial infection.
Timeline
2011 to 2026: Duration of development research for the spinach-based treatment.
Late 2026: Silvec Biologics plans to initiate work with Florida growers.
The Tech Race
This registration follows over a decade of research within the Citrus Research and Field Trial program to combat the bacterial infection destroying groves. It provides a new biological alternative as researchers race to find scalable treatments to mitigate the impact of citrus greening on commercial yields.
The treatment will be available to Florida growers through planned field trials starting in late 2026. This intervention offers an alternative for managing groves currently affected by the bacterial disease without requiring genetic modification of the citrus stock.
The takeaway
This regulatory milestone transitions the spinach-compound treatment from a decade-plus research phase into practical application. Growers and agricultural investors should monitor the results of the 2026 Florida field trials to gauge the viability of this biological approach against current chemical or cultural controls.
What happens next
Silvec Biologics is scheduled to begin field-based collaborations with Florida growers in late 2026.
Further reading
For broader trends in plant pathology and agricultural innovation, explore our Botany coverage.
Source note: This article includes information reported by AG INFORMATION NETWORK OF THE WEST.
Live Poll
Should the agriculture industry prioritize adopting new biological treatments to combat crop diseases?
